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Introduction
Sepsis is a devastating health problem taking millions of 
lives every year in neonatal ICUs (NICUs) all around the 
world [1,2]. Тhe original hypothesis addressing the patho-
genesis of sepsis that blamed aggressive immune activity 
for sepsis-related health problems and death was 
countered by new facts showing that sepsis is best 
explained by generally reversible mitochondrial and 
cellular dysfunction [3]. Taking into account that an 
activated immune system and dysfunctional mitochon-
dria represent the two most potent sources of reactive 
molecular species and that many reports imply an impor-
tant role of reactive oxygen and nitrogen species (ROS 
and RNS) in the pathogenesis of sepsis, we recently out-
lined the main redox events that are interconnected in a 
self-sustaining and self-promoting pathological process 
we term the ‘sepsis redox cycle’, which may result in the 
total loss of cellular and organ function [3]. Th is review is 
aimed at elucidating the ‘sepsis redox cycle’ in neonatal 
sepsis (the neonatal ‘sepsis redox cycle’), and represents a 
logical extension of our previous review, which was based 
on the available data addressing sepsis in adults. A com-
plete picture of neonatal sepsis and therapy potentials 
requires a thorough understanding of the developmental 
diff erences that separate the pathogenesis of adult and 
neonatal sepses. While adult and neonatal sepses share 
some common features, there are some substantial diff er-
ences: higher incidence and mortality rates are observed 
for adult sepsis, while long-term eff ects are worse in 
neonatal sepsis survivors. Fortunately, in developed 
countries neonatal sepsis is rare (up to 9 cases per 1,000 
newborns). An epidemiological study performed in the 
US has illustrated that the incidence of sepsis is age-
related, being highest in people over 65  years of age 
(26.2/1,000), while in infants under 1  year of age it was 
5.3/1,000 [4]. In a population of sepsis patients admitted 
to ICUs and given both antibiotics and supportive care, 
neonatal sepsis is substantially less lethal (3 to 10% 
mortality rate in developed countries) [5-7] compared to 
sepsis in adults (mortality rate of around 35%) according 
to the latest Surviving Sepsis Campaign report for 2010 
[8]. Th is is somewhat surprising bearing in mind that 
neonatal sepsis has been a subject of signifi cantly less 
research. We have undertaken a brief systematic search 
of PubMed (electronic database of the US National 
Library of Medicine) looking for articles that contain: 
(i)  the term ‘neonatal sepsis’ or a combination of the 
words sepsis and neonatal, neonate, newborn or baby in 
the title/abstract section; and (ii)  the word sepsis but 
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neither of the previous terms in the same section. While 
the fi rst search returned some 4,000 results, the second 
search returned around 50,000 papers, implying that 
comparatively less is known about neonatal sepsis. 
Th erefore, signifi cantly lower mortality rates in NICUs 
do not seem to be related to more developed therapeutic 
approaches and fi nely tuned care in comparison to ICUs, 
but to specifi c diff erences between neonatal and adult 
sepsis patho genesis, making the former less life-
threatening. On the other hand, it seems that those who 
survive sepsis are more likely to develop diff erent 
morbidities later in life if sepsis episode(s) took place 
during the fi rst 4 weeks of life (neonatal period). It should 
be stressed that the long-term eff ects of sepsis have not 
been well documented, and there are not many studies 
on this issue. Never theless, two cohort studies on 
extremely low birth weight neonates reported a 
signifi cantly increased incidence of a number of diff erent 
morbidities at the age of 18 to 22  months in the 
population of neonatal sepsis survivors in comparison to 
age- and birth-weight-matched con trols; these include 
respiratory distress syndrome, broncho pulmonary 
dysplasia, periventricular leukomala cia (PVL), severe 
intraventricular hemorrhage, cerebral palsy, and vision 
and hearing impairments [9,10]. A retro spective cohort 
study documented that only 28% of neonatal septic shock 
survivors were alive and were considered normal 
18  months after the septic shock episode(s) [11]. In 
contrast, adult severe sepsis survivors generally show 
recovery of baseline or near-normal values of general 
health and most of the other ‘quality of life’ parameters 
(only) 6  months after the sepsis episode [12]. Although 
diff erent neurocognitive impairments have been reported 
in adult sepsis survivors, a consistent fi nding across 
investigations is that no associations exist between the 
indicators of severity and the development of unfavour-
able neurocognitive outcomes in survivors of critical 
illness [13]. Adult sepsis studies examining morbidities 
other than these are not available, but there are data on 
outcomes in an acute respiratory distress syndrome 
cohort and in a general population of ICU survivors. 
Th ese surveys showed that nearly all acute respiratory 
distress syndrome patients fully recover lung function 
within 1 year [14], while ICU patients that survived renal 
failure almost always experience a complete recovery of 
renal function [15]. Such disparity in long-term eff ects 
further points out that there are signifi cant diff erences 
between the mechanisms of neonatal and adult sepsis. 
Th erefore, to come to new conclusions and the mecha-
nism of neonatal sepsis pathogenesis, we will compare 
neonatal and adult sepsis step-by-step, from initial events 
all the way down to cellular dysfunction, focusing on 
redox processes but not underestimating other 
components, such as immune system activity. It should 
be stressed here that data available on neonatal sepsis are 
rather limited, as illustrated by the number of published 
papers. Th is may represent the reason why some previous 
reviews addressing mechanisms of neonatal sepsis failed 
to resist the temptation to combine data from neonatal 
with those from adult sepsis studies. Th is is not the case 
with the present review, as we have carefully separated 
neonatal from adult sepsis, underlining the caveats in the 
state-of-the-art knowledge on the former.
Redox mechanisms in neonatal sepsis
Pathogen-provoked events in the plasma
Sepsis is a process that is initiated by pathogens, followed 
by increased immune system activity that activates a 
redox cascade in the intracellular compartment, and ends 
in cell and organ dysfunction [3]. Th e fact that pathogens 
are the initiators of a process that is thereafter principally 
independent of their presence is substantiated by the fact 
that a large percentage of septic adults (10 to 40% [16,17]) 
and neonates (over 50% in some studies [18,19]) show 
negative blood cultures at some points during the disease 
course. Infl ammatory responses related to tachycardia, 
tachypnea, hyperthermia or hypothermia and leuko cy-
tosis most commonly triggered by infection could also be 
present following trauma, burn injury and various other 
pathogen-unrelated insults [20]. Finally, the fact that 
neonates are comparatively more susceptible to infec-
tions but less to sepsis than adults [21] implies that 
pathogens do not play a central role in sepsis develop-
ment. How ever, pathogens do induce an innate immune 
system response, which represents the second step in 
sepsis pathogenesis.
Th ere are several key developmental diff erences in the 
host response to infection that clearly delineate neonatal 
sepsis as a separate entity from adult sepsis. Th e most 
obvious dissimilarity lays in the activity of the innate 
immune system. In comparison to the innate immune 
system and infl ammatory response in adults, the neonatal 
system under septic conditions has: (i) a lower capacity to 
generate ROS and RNS; (ii)  a diff erent cytokine profi le; 
(iii)  a low neutrophil pool and a reduced capacity for 
increasing progenitor cell proliferation; (iv)  neutrophil 
granulocytes exhibiting quantitative and qualitative abnor-
malities; (v)  and neutrophils showing reduced func tion 
and an impaired capacity for migration, chemotaxis, 
endothelial adherence, and phagocytosis [22-24]. Th e 
fi rst two points are particularly important here and 
require further explanation.
Neutrophils, macrophages and endothelial cells repre-
sent the fi rst line of defence against pathogens and for 
this purpose they are equipped with diff erent ROS and 
RNS that provoke oxidative damage and kill the invaders 
[3]. However, some of the reactive species produced, such 
as hydrogen peroxide (H2O2) and nitric oxide (•NO) are 
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capable of crossing the cellular membrane to enter the 
intracellular compartment, where they may initiate and 
participate in the ‘sepsis redox cycle’ [3]. While this is 
true for adult sepsis, data show that when challenged by 
pathogens or experimental inducers, the oxidative burst 
performed by the neonatal immune system is signifi cantly 
less pronounced than in adult sepsis (Table 1). As a result 
of lower ROS-generating activity of the innate immune 
system, neonatal plasma generally does not show positive 
markers of oxidative stress, which is in strong contrast to 
the results obtained in adults [3]. For example, Cherian 
and colleagues [25] reported that there were no signifi -
cant changes in the levels of ascorbate, glutathione 
(GSH), and oxidative stress biomarkers in the blood of 
neonates and babies with sepsis when compared to age-
matched controls. Another study showed merely a slight 
increase in the level of lipid peroxidation products in the 
serum of septic neonates in comparison to controls [26]. 
A transient increase of total hydroperoxide level was 
reported in the blood of septic newborn piglets, while 
biological antioxidant potential was even increased at 
some time points during the 6  hour monitoring period 
[27]. Hydrogen peroxide has a central place in initiation 
of the ‘sepsis redox cycle’, so lower prooxidative activity of 
the neonatal immune system may account for the low 
incidence of sepsis in neonates. It is noteworthy that one 
Cochrane study showed that the supplementation of 
vitamin E, which is involved in free radical scavenging in 
the blood, signifi cantly increases the risk of sepsis in 
neonates [28]. Th is may be attributed to vitamin E-
mediated suppression of the already weak oxidative 
activity of the neonatal immune system, resulting in 
decreased bactericidal capacity.
While many cytokines are present at similar levels in 
the blood of neonatal and adult septic patients, some 
show substantial diff erences. Table 2 lists results from a 
series of studies documenting notably higher production 
of IL6 and IL8 and generally lower production of TNF-α 
in neonatal sepsis. In addition, IL6 and IL8 are signifi -
cantly increased in the serum of septic neonates in 
comparison to uninfected peers, and probably represent 
the best early diagnostic markers for neonatal sepsis 
among the components of the immune system [29,30]. 
For example, Küster and co-workers [31] showed that the 
level of IL6 in the neonatal plasma increases approxi-
mately ten-fold two days before clinical diagnosis of sepsis. 
Other groups showed levels of IL6 and IL8 increased in 
septic neonates by approximately 20- and 8-fold, respect-
ively [32], and 200 and 15 times, respectively, in compari-
son to healthy controls [33]. It is impor tant to note here 
that plasma concentrations refl ect only a small portion of 
the IL8 blood pool (approximately 10%; most of IL8 is cell 
associated) [34]. Th is is also likely to be the case for IL6. 
Altogether, these data imply that while TNF-α represents 
the central mediator of sepsis in adults [35], this role is 
played by IL6 and IL8 in the pathogenesis of neonatal 
sepsis.
Intracellular redox changes in neonatal sepsis
Pro-oxidative and pro-infl ammatory events in the plasma 
may have a strong impact on the intracellular milieu. In 
adult sepsis, H2O2 and TNF-α activate NF-κB, which has 
a special place in sepsis development [3]. Its activity is 
signifi cantly higher in septic non-survivors in comparison 
to controls and survivors and may predict sepsis-related 
mortality [36,37]. In spite of diff erent redox settings and 
cytokine profi les, NF-κB is also activated in neonatal 
sepsis. Several studies showed that the stimulation of 
diff erent neonatal cell types by lipopolysaccharide (LPS) 
results in the activation of NF-κB, which was similar to or 
even higher than in adult systems [38-42]. Kenzel and 
colleagues [43] showed using a model of neonatal sepsis 
and two diff erent bacterial species that NF-κB-dependent 
expression increases several fold in the presence of 
pathogens, while an in vivo investigation on newborn 
septic rats showed that NF-κB was activated in the lungs, 
Table 1. The capacity of neonatal versus adult immune system cells to generate reactive oxygen species
 Group
Cell type Stimulus Parameter Neonate Adult Reference
Bovine polymorphonuclear leukocytes PMA •O2
-/106 cells/5 minutes (nmol) 5.7 ± 0.8 9.6 ± 2.1 (P < 0.01) [93]
Human neutrophils fMPL Relative production of •O2
- per minute 8.0 ± 3.6 10.6 ± 2.1 (P < 0.05) [94]a
Human neutrophils PMA Relative production of •O2
- per minute 15.3 ± 6.8 27.5 ± 4.8 (P < 0.01) [94]a
Human granulocytes fMPL Maximal ROS production in arbitrary units 24 ± 6 57 ± 8 (P < 0.01) [95]
Human alveolar macrophages PMA Intracellular •O2
- production (pmol/3 × 105 cells) 26 ± 6 94 ± 22 (P < 0.05) [96]
Human alveolar macrophages Opsonized zymosan Intracellular •O2
- production (pmol/3 × 105 cells) 50 ± 16 164 ± 22 (P < 0.05) [96]
Human mononuclear phagocytes IFN-γ •O2
- release (nmol/106 cells) 20 ± 4 31 ± 5 (P < 0.01) [97]
aWe extracted and pooled the results provided in the manuscript and performed statistical analysis using Statistica 6.0 (StatSoft, Inc., Tulsa, OK, USA); statistical 
signifi cance was determined by the means of non-parametric two-tailed Mann-Whitney test. fMPL, N-formyl-methionyl-leucyl-phenylalanin (degradation product of 
bacterial proteins); IFN, interferon; •O2
-, superoxide; PMA, phorbol 12-myristate 13-acetate; ROS, reactive oxygen species.
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liver, and spleen [44]. Recent studies shine a new light on 
NF-κB activation in neonatal sepsis. Manna and co-
workers [45,46] have shown that IL8 represents a NF-κB 
activator in diff erent cell types. IL8 followed a time- and 
dose-dependent pattern of NF-κB activation that was 
similar to TNF-α. However, IL8 is approximately two 
orders of magnitude less eff ective as an NF-κB activator 
in comparison to TNF-α - that is, similar levels of NF-κB-
regulated expression have been observed with IL8 at a 
concentration of 1 nM as with TNF-α at 10 pM [45,46]. 
IL6 also represents an activator of NF-κB-regulated 
expression, and seems to be less effi  cient in comparison 
to TNF-α [47]. It is important to note here that IL6 binds 
to trans-membrane IL6 receptors, or forms a complex 
with soluble IL6 receptors, which associates with two 
mole cules of the signal transducing protein gp130, 
thereby initiating intracellular signalling and NF-κB 
activation [48]. Th e lesser ability of IL6 and IL8 to 
activate NF-κB-regulated transcription in comparison to 
TNF-α should be considered a possible reason for the 
lower incidence and mortality rates in neonatal sepsis. 
Th e levels of IL6 and IL8 increase during the fi rst 12 to 
24  hours of neo natal sepsis development, following 
which they gener ally decline in the blood to normal 
values characteristic of infection-free neonates [29]. Th is 
is in line with their role as initiators of a cascade of events 
that is independent of infl ammatory processes thereafter.
NF-κB binds to DNA to enable the initiation of the 
transcription process of a number of genes, two of them 
encoding redox-active enzymes: inducible nitric oxide 
(•NO) synthase (iNOS) and cyclooxygenase-2 (COX-2; 
which generates superoxide (•O2-) as a by-product) [3]. 
Pertinent to the role of IL8 and IL6 in neonatal sepsis, it 
has been shown that the exposure of cells to these 
cytokines results in the expression/up-regulation of 
iNOS and COX-2 [45,49]. Th e increased expression and 
activity of iNOS and COX-2 have been documented in 
various tissues (brain, skeletal muscle, lung, and cardiac 
tissue) of rodent and porcine models of neonatal sepsis 
when initiated using Escherichia coli, GBS or LPS [41,50-
57]. Th e importance of the activation of iNOS expression 
in sepsis pathogenesis is substantiated by the fi ndings of 
Mittal and co-workers [50], who showed that iNOS-/- 
newborn mice infected with E. coli display no disruption 
of the blood-brain barrier, a reduced infl ammatory 
response and normal brain physiology. Generally, iNOS 
is absent in resting neonatal cells and is triggered by 
pathogens or cytokines, leading to the production of •NO 
in the micromolar range [52]. Th is is much higher in 
comparison to the capacity of constitutively expressed 
endothelial nitric oxide synthase, which produces local 
•NO concentrations in the nanomolar range [50]. Signifi -
cantly increased •NO production in septic neonates and 
neonatal sepsis models has been verifi ed in a number of 
studies [50,58-60]. •NO is known to provoke the inhibi-
tion of the electron transport chain in mitochondria in 
adult sepsis [61].
In addition to COX-2-mediated •O2- production, this 
radical is produced in neonatal sepsis by NADPH oxidase 
and in mitochondria showing inhibited respiration. It has 
been shown that LPS treatment of rat neonatal cardio-
myocytes leads to two-fold increased NADPH oxidase 
expression and •O2- generation [40]. IL6 may promote 
NADPH oxidase •O2--producing activity [62], while 
Table 2. Levels of IL6, IL8 and TNF-α in neonatal versus adult sepsis
                                                            Group  Other cytokines
     showing
Sample Stimulus Cytokine Neonate Adult no diff erence Reference
Human blood GBS IL6 (pg/ml) 100 ± 105 14 ± 13 (P = 0.003) IL-1β [98]
  IL8 3,355 ± 1,762 1,109 ± 452 (P = 0.01)
  TNF-α 592 ± 349 481 ± 261 (NS)
Human blood E. coli IL6 (pg/ml) 1,000 ± 0 783 ± 84 (P = 0.02) IL-1β [98]
  IL8 7,120 ± 751 4,995 ± 472 (P = 0.003)
  TNF-α 952 ± 167 908 ± 62 (NS)
Human blood HSV-1 IL6 (pg/ml) 3,920 ± 3750 360 ± 190 (P = 0.033) - [99]a
  IL8 (ng/ml) 32 ± 38 6.5 ± 1.7 (P = 0.066)
Human mononuclear cells 11 bacterial IL6 (ng/ml) 104 ± 36 59 ± 20 (P < 0.01) IL10 [100]a
 speciesb TNF-α 16 ± 14 17 ± 15 (NS) IL12
Human monocytes LPS TNF-α (pg/ml) 610 2,230 (P < 0.05) - [101]
Human monocytes LPS IL6 (ng/ml) 3.7 ± 1.1 1 ± 0.3 (P < 0.05) - [102]
  TNF-α 0.6 ± 0.2 3.3 ± 1.3 (P < 0.05)
Human blood LPS TNF-α (ng/ml) 1.47 ± 1.03 3.89 ± 1.94 (P < 0.05) IL2 [38]
     IL4
     IFN-γ
aWe extracted and pooled the results provided in the manuscripts and performed statistical analysis. bEleven diff erent bacterial species from intestinal fl ora, each 
being studied separately. GBS, Group B streptococcus; HSV-1, herpes simplex virus type-1; IFN, interferon; NS, not signifi cant.
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Miyoshi and colleagues [63] have demonstrated using 
endothelial cells from umbilical vein that IL8 is directly 
involved in the activation of NADPH oxidase in sepsis. 
Investigations of mitochondrial function in neonatal sepsis 
are not very extensive, whereas data on •O2- produc tion 
in mitochondria under such settings are missing. 
Nevertheless, it has been shown using cytokine-treated 
cardiac myocytes and hepatocytes, both isolated from rat 
neonates, that •NO inhibits the electron transport chain 
and normal mitochondrial functioning [64-66]. A study 
on hepatocytes from suckling rats with LPS-induced 
sepsis showed that intra-mitochondrial O2 consumption 
was decreased two-fold in comparison to controls, and 
that the mitochondria exhibited altered morphology, 
being swollen with indistinct cristae, disrupted mem-
branes, and outer membrane fusion [67]. Th e dysfunction 
of mitochondria and energy failure in neonatal sepsis are 
also implicated by the fact that septic neonates experi-
ence rapidly decreased O2 consumption, as well as lower 
heat production and body temperature in comparison to 
healthy peers [68]. However, in contrast to adult sepsis, 
where ATP depletion has been well documented [3], the 
changes in ATP level have not been amply investigated in 
neonates. Only two studies have been performed on 
hepatocytes obtained from rat neonates very early in 
sepsis (2 hours after LPS injection), showing that there is 
no signifi cant decrease in ATP levels [67,69]. Th is may be 
due to the ability of neonatal cells to compensate for 
mitochondrial dysfunction by extra-mitochondrial ATP 
production [67]. Th e compensation leads to excessive 
consumption of glucose and increased extra-mitochon-
drial O2 consumption, which have been documented in 
these studies [67,69]. Such production, however, yields 
only small amounts of ATP, which may maintain energy 
metabolism in balance for a short time, but with non-
functioning mitochondria, glycolysis cannot prevent ATP 
depletion and cellular dysfunction in the long run. Th is 
remains to be substantiated by evidence on levels of ATP 
later in the course of neonatal sepsis development.
Superoxide reacts with •NO to produce peroxynitrite 
(ONOO-), but there are no direct data showing the 
production and role of ONOO- in neonatal sepsis. 
However, the formation of ONOO- represents a simple 
chemical consequence of the co-existence of •O2- and 
•NO [70], which most likely does not depend on cell age 
or type. Arstall and co-workers [71] showed that in neo-
natal rat ventricular myocytes exposed to cytokines, a 
sequence of events develops involving activation of iNOS 
and increased •O2- and ONOO- production. Mitochon-
dria are specifi cally targeted by highly reactive products 
of ONOO- decomposition - •OH and •NO2 [3]. Th e fi rst is 
notoriously reactive and provokes damage to membranes, 
proteins and DNA while •NO2 binds to proteins leading 
to increased susceptibility to protease-mediated degradation 
[3]. Pertinent to this, Fukumoto and co-workers [66] have 
shown that ONOO- drastically aff ects the function ing of 
mitochondria isolated from the hearts of rat neonates.
Th e main consequence for •O2- is to be dismutated to 
H2O2 in mitochondria by Mn superoxide dismutase 
(MnSOD) or in the cytoplasm by CuZnSOD. Hydrogen 
peroxide provokes further NF-κB activation [72], thus 
closing the redox loop. Pertinent to this, it has been 
reported that the expression of COX-2 in LPS-treated 
neonatal rat cardiomyocytes can be prevented by the 
inhibition of •O2- production. Peng and colleagues [40] 
also showed that LPS-induced NF-κB activation is 
depen dent on NADPH oxidase-mediated activity, which 
leads to increased levels of H2O2. Th ese facts imply that 
extracellular stimuli (IL6, IL8, LPS) only push the cascade 
of events by activating NF-κB-regulated expression, and 
the cascade then reaches maximum potential through 
H2O2-mediated activation, most likely representing a 
critical step in the development of neonatal sepsis. It is 
note worthy that CuZnSOD over-expression is not 
benefi cial in neonatal mouse brain cells showing mito-
chondrial dysfunction, implying the negative role of its 
product - H2O2. In contrast, over-expression of the H2O2-
removing enzyme GSH peroxidase (GPx) was shown to 
be brain-protective [73]. In line with this, a Cochrane 
systematic review showed that the supplementation of 
selenium, which is necessary for GPx synthesis, was 
associated with a signifi cant reduction in neonatal sepsis 
incidence [74]. It should be stressed that mitochondria 
base their defence against H2O2 on GPx activity [75]. 
Clearly, under conditions in which cellular respiration is 
obstructed, such as neonatal sepsis, the main problem 
comes from H2O2, which may leak from mitochondria or 
is produced by CuZnSOD in the cytoplasm. Hence, the 
positive eff ects of GPx in neonatal sepsis may be 
attributed to its ability to stop the redox loop.
Some other processes that have been described in adult 
sepsis still remain inconclusive in septic neonates. For 
example, the sequence of events involving ONOO--
mediated activation of poly(ADPribose) polymerase that 
leads to augmented •O2- production on mitochondrial 
complex I in adult sepsis [3] has not been studied in neo-
natal sepsis. In adult sepsis, •NO is known to leak from 
cells into the blood, leading to methaemoglobin forma-
tion, hemolysis and increased iron availability, thus 
boosting pathogen proliferation [3]. Pertinent to this, 
there is only one obscure report showing higher 
methaemoglobin level in septic neonates in comparison 
to healthy controls [76].
Figure 1 amalgamates the key redox events in neonatal 
sepsis into a self-sustaining and self-promoting neonatal 
‘sepsis redox cycle’. It is important to note that we have 
presented only those steps in the pathogenesis of 
neonatal sepsis that have been substantially documented, 
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while some others remain to be further investigated. 
Instead of shutting down upon pathogen eradication or in 
the immune hypoactive phase, the neonatal ‘sepsis redox 
cycle’ continues to drain energy and prevents normal 
function to be re-established due to a positive feedback 
loop. Th e pathophysiological redox profi le of one cell can 
spill over to surrounding tissue due to the ability of H2O2 
and •NO to cross membranes, thus leading to organ failure.
The outcome
While in adults sepsis-related cellular dysfunction is 
generally reversible [3], in neonates this seems to be far 
from the truth. In this fragile population, nervous, 
respira tory, and cardiovascular systems that are still 
developing are vulnerable to sepsis-provoked stress, 
which may lead to brain (PVL, intraventricular hemor-
rhage, cerebral palsy), lung (respiratory distress syndrome 
and bronchopulmonary dysplasia), and heart injury 
(patent ductus arteriosus), as well as vision and hearing 
impairments [10,77-79].
Together, a fall in ATP concentration and oxidative 
stress exerted on mitochondria and other compartments, 
both resulting from the neonatal ‘sepsis redox cycle’, may 
lead to mitochondrial permeability transition pore 
opening with eventual organelle swelling and cytochrome 
c release [80]. Once in the cytoplasm, cytochrome c can 
Figure 1. The neonatal ‘sepsis redox cycle’. IL6 and IL8 activate NF-κB, resulting in increased inducible nitric oxide synthase (iNOS) and 
cyclooxygenase-2 (COX-2) expression. IL6 and IL8 also activate NADPH oxidase. iNOS produces large amounts of nitric oxide (•NO), which 
inhibits the electron transport chain (ETC), leading to increased mitochondrial superoxide (•O2
-) production. COX-2 and NADPH oxidase produce 
cytoplasmic •O2
-, where it is dismutated by CuZn superoxide dismutase (SOD) to H2O2. In mitochondria, 
•O2
- may react with •NO from cytoplasm 
to produce peroxynitrite (ONOO-), which is protonated to ONOOH and further decomposed to •OH and •NO2. Alternatively, 
•O2
- is dismutated by 
MnSOD. If not degraded by GSH peroxidase (GPx), H2O2 leaks from mitochondria. H2O2 strongly activates NF-κB, thus closing and further promoting 
the redox loop. Mitochondria with an inhibited electron transport chain and damaged by •OH and •NO2
 produce less ATP, which leads to energy 
depletion and cellular dysfunction. sIL6R, soluble IL6 receptor; IL8R, IL8 receptor.
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bind to apoptotic protease activating factor 1 (APAF-1) 
and thus activate caspase-9, which in turn activates 
caspases-3 and -7, culminating in apoptosis [81]. 
Proliferating cells in neonatal patients may be particularly 
susceptible to apoptosis, taking into account increased 
demands for energy in such cells. In addition, APAF-1, 
caspase-3 and -9, and the pro-apoptosis Bcl-2 family 
member Bim are present in higher concentrations in 
developing neonatal brain in comparison to adult brain 
tissue [82,83]. Bacteraemia is known to further promote 
caspase-3 gene expression in neonates [51], while the 
changes in mito chondrial morphology characteristic of 
apoptosis have been documented to develop in a neonatal 
sepsis model [67]. In contrast, immunohistochemical 
analysis has shown that apoptosis generally does not 
develop in adult sepsis [3].
Particularly vulnerable to oxidative injury and suscep-
tible to apoptosis are oligodendrocyte progenitors and 
subplate neonatal neurons, which represent the major 
cellular targets in the pathogenesis of white matter 
injury/PVL in neonatal sepsis [84-86]. Hence, brain-
related morbidities in neonatal sepsis survivors may be 
explained by neonatal ‘sepsis redox cycle’-provoked 
apoptosis in these specifi c cell types. Pertinent to this, the 
levels of IL6 and IL8 in the blood of septic neonates 
showed positive correlation with poor mental and 
psycho motor characteristics at the age of 2 [87]. Th e 
increased odds of developing visual impairments in neo-
natal sepsis survivors may be explained by the increased 
susceptibility of oligodendrocytes in the developing optic 
nerve to apoptosis [88], as well as by the fact that subplate 
neurons, which may be aff ected in sepsis, are required for 
normal visual cortical development [85]. Respiratory 
morbidities may be related to the fact that during early 
postnatal alveolar formation, the lung tissue undergoes a 
physiological remodelling involving apoptosis of distal 
lung cells [89]. For example, autopsy analysis of lungs of 
neonates who have died of fatal respiratory failure 
showed an elevated number of apoptotic cells in compari-
son to autopsy samples obtained from controls with no 
lung disease [90,91]. Finally, cardiovascular morbidities 
may be explained by a lower resistance of neonatal 
cardiomyocytes and cardiomyoblasts to apoptosis in com-
parison to adult cardiomyocytes. Activation of caspase-9 
and -3, and cell death occur earlier and are more pro-
nounced, while the levels of expression of the mito chon-
drial pro-apoptotic protein APAF-1 were signifi cantly 
higher in neonatal compared to adult cells exposed to 
oxidative stress [92]. In summary, while the neonatal 
‘sepsis redox cycle’ in most cells types may lead to 
reversible dysfunction, in others that are proliferating 
and sensitive to oxidative stress, it may initiate apoptosis, 
which seems to account for most morbidities found 
following a neonatal sepsis episode.
Conclusion
Although sharing many features with adult sepsis, 
neonatal sepsis exhibits its own hallmarks. Th e neonatal 
‘sepsis redox cycle’ is initiated by IL6 and IL8, and further 
promoted by intracellular H2O2 production, while in 
adult sepsis TNF-α and extracellular H2O2 represent the 
initiators of the intracellular chain of redox events. Th e 
fact that the latter two are more eff ective NF-κB 
activators may explain why adult sepsis is more frequent 
and more deadly in comparison to neonatal sepsis. On 
the other hand, a higher susceptibility of developing cells 
to apoptosis may explain the more frequent and wider 
spectrum of morbidities found in neonatal sepsis sur-
vivors. Current strategies in neonatal sepsis treatment 
are focused on pathogen eradication by an early appli-
cation of antibiotics, which is no surprise since neonatal 
sepsis represents one of the most rapidly fulminating 
clinical diseases in NICUs. However, the increased 
incidence of fungal and coagulase-negative staphylo-
cocci-provoked sepsis, potentially increased antibiotic 
resistance, and sporadic outburst of resistant strains in 
NICUs require an additive (early and safe) therapeutic 
approach that is benefi cial independently of the pathogen 
that initiated the process. In light of the integrated 
processes described here, it is clear that such approaches 
should target specifi c steps in the neonatal ‘sepsis redox 
cycle’.
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